A new experimental drug developed to target HPV-related cervical disease could transform the way stage 0 cervical cancer and precancerous cervical lesions are treated in the future. The Indian Council of Medical Research (ICMR) has licensed the anti-HPV therapeutic candidate SHetA2 to Emcure Pharmaceuticals for further development, marking a significant step toward a potential non-surgical treatment option.
Although the drug is still awaiting clinical trials to establish its safety and effectiveness in humans, researchers believe it could eventually provide an alternative to surgery for women diagnosed with precancerous cervical changes.
SHetA2 targets HPV-infected cells while protecting healthy tissue
SHetA2 was developed through a collaboration between scientists at ICMR’s National Institute of Cancer Prevention and Research (NICPR) and the University of Oklahoma’s Stephenson Cancer Center in the United States.
The therapy is designed to selectively destroy HPV-induced precancerous and cervical cancer cells without damaging surrounding healthy tissue. If clinical studies confirm its benefits, SHetA2 could become one of the first targeted therapies capable of treating cervical intraepithelial neoplasia (CIN) without requiring surgical intervention.
The growing use of cervical cancer screening has increased the detection of CIN, allowing doctors to identify and treat abnormal cell changes before they develop into invasive cancer.
Why this development matters
India continues to carry one of the world’s largest cervical cancer burdens. Nearly 80,000 women are diagnosed with cervical cancer every year, while more than 42,000 deaths are reported annually, making it the country’s second most common cancer among women after breast cancer.
Despite the availability of HPV vaccines and screening programmes, limited awareness, delayed diagnosis, and uneven access to healthcare continue to contribute to the high disease burden.
Earlier this year, the government launched a nationwide HPV vaccination programme offering free Gardasil-4 vaccines to 14-year-old girls. The initiative aims to protect an estimated 1.15 crore girls and reduce future cervical cancer cases across the country.
How stage 0 cervical cancer is currently treated
Cervical intraepithelial neoplasia is classified based on the severity of abnormal cell growth.
- CIN 1: Mild cell changes that often resolve naturally.
- CIN 2: Moderate abnormalities with a higher risk of progression.
- CIN 3: Severe precancerous changes that can develop into invasive cervical cancer if left untreated.
Stage 0 cervical cancer, also known as carcinoma in situ, occurs when abnormal cells remain confined to the surface of the cervix and have not spread into deeper tissues.
Current treatment primarily involves surgical procedures to remove the affected tissue. While these procedures are highly effective in preventing cancer progression, they may affect cervical structure and, in some cases, future pregnancies.
A targeted drug therapy like SHetA2 could preserve healthy cervical tissue while eliminating HPV-driven abnormal cells, offering a less invasive treatment option for women, particularly those of reproductive age.
Clinical trials remain the next critical step
Despite its promise, SHetA2 is still in the development phase and is not yet available for patients.
Researchers must complete extensive clinical trials to determine the drug’s safety, ideal dosage, possible side effects, and overall effectiveness compared with current surgical treatments before regulatory approval can be considered.
For now, the licensing agreement represents an important scientific milestone rather than an immediate change in medical practice.
Potential beyond cervical cancer
Scientists are also exploring whether the same therapeutic approach could be used against other cancers linked to high-risk human papillomavirus (HPV).
Since HPV is associated with cancers affecting the anus, penis, and certain head and neck regions, successful clinical outcomes with SHetA2 could pave the way for future research into treating other HPV-related precancerous conditions and cancers using targeted drug therapy.
Key Highlights
- ICMR has licensed the anti-HPV drug candidate SHetA2 to Emcure Pharmaceuticals for further development.
- The experimental therapy aims to treat stage 0 cervical cancer and precancerous cervical lesions without surgery.
- SHetA2 selectively targets HPV-infected abnormal cells while preserving healthy tissue.
- Clinical trials are still required to confirm the drug’s safety and effectiveness before approval.
- India reports nearly 80,000 new cervical cancer cases and over 42,000 deaths every year.
- Researchers believe the therapy could eventually be explored for other HPV-related cancers.
FAQs
Q1. What is SHetA2?
SHetA2 is an experimental anti-HPV drug candidate developed to target precancerous and cervical cancer cells while protecting healthy tissue.
Q2. Can SHetA2 replace surgery for stage 0 cervical cancer?
Not yet. The drug is still undergoing development, and clinical trials must prove its safety and effectiveness before it can be used as an alternative to surgery.
Q3. What is stage 0 cervical cancer?
Stage 0 cervical cancer, also called carcinoma in situ, is the earliest stage in which abnormal cells are confined to the surface of the cervix and have not spread to deeper tissues.
Q4. Why is this development important for women?
If successful, SHetA2 could offer a less invasive treatment that preserves healthy cervical tissue and may reduce the impact of surgery on future pregnancies.
Q5. Who is developing SHetA2?
The drug was developed through a collaboration between ICMR’s National Institute of Cancer Prevention and Research (NICPR) and the University of Oklahoma’s Stephenson Cancer Center, and has now been licensed to Emcure Pharmaceuticals.
Q6. Could SHetA2 help treat other cancers?
Researchers believe the same approach may eventually be studied for other HPV-related cancers, including those affecting the anus, penis, and parts of the head and neck.
